

FINANCIAL TEAR SHEET

CORPORATE PROFILE

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

PRIMARY IR CONTACT

Investor Relations
Phone: 647-479-9825
E-mail: ir@aptose.com

STOCK PERFORMANCE

APTO (COMMON STOCK)

Exchange	TSX (Canadian Dollar)
Price	Can\$1.85
Change (%)	▼ 0.1 (5.13%)
Volume	28,069
52 Week Low	Can\$1.05
Market Cap	Can\$46,707,870
Rolling EPS	-1.00
PE Ratio	0
Shares Outstanding	23,952,754

Data as of August 16, 2017 3:59 p.m. ET



APTO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	\$1.45
Change (%)	▼ 0.03 (2.03%)
Volume	157,924
52 Week Low	\$0.78
Market Cap	\$35,450,076
Rolling EPS	-0.77
PE Ratio	0
Shares Outstanding	23,952,754

Data as of August 16, 2017 3:59 p.m. ET



RECENT PRESS RELEASES & UPCOMING EVENTS

August 8, 2017

Aptose Reports Results for the Second Quarter Ended June 30, 2017

August 3, 2017

Aptose Biosciences to Present at Canaccord Genuity 37th Annual Growth Conference

August 1, 2017

Aptose To Release Second Quarter Ended June 30, 2017 Financial Results and Hold Conference Call on August 8, 2017

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
August 9, 2017	6-K
August 8, 2017	6-K
August 3, 2017	6-K
August 1, 2017	6-K

CORPORATE GOVERNANCE

William G. Rice, Ph.D.	Chairman, President & Chief Executive Officer
Daniel D. Von Hoff, M.D., F.A.C.P.	Senior Vice President, Medical Affairs
Stephen B. Howell, M.D.	Acting Chief Medical Officer
Avanish Vellanki	Senior Vice President, Chief Business Officer
Gregory Chow	Senior Vice President, Chief Financial Officer
Elizabeth Williams	Vice President, Finance and Administration
Ernest Kitt	Vice President, Development and Technical Operations

Data provided by Nasdaq. Minimum 15 minutes delayed.